147 related articles for article (PubMed ID: 26261503)
1. Expression of HMGB1/RAGE protein in renal carcinoma and its clinical significance.
Qie GQ; Wang CT; Chu YF; Wang R
Int J Clin Exp Pathol; 2015; 8(6):6262-8. PubMed ID: 26261503
[TBL] [Abstract][Full Text] [Related]
2. Receptors for advanced glycation end products (RAGE) is associated with microvessel density and is a prognostic biomarker for clear cell renal cell carcinoma.
Guo Y; Xia P; Zheng JJ; Sun XB; Pan XD; Zhang X; Wu CZ
Biomed Pharmacother; 2015 Jul; 73():147-53. PubMed ID: 26211596
[TBL] [Abstract][Full Text] [Related]
3. High ASMA
Amornsupak K; Jamjuntra P; Warnnissorn M; O-Charoenrat P; Sa-Nguanraksa D; Thuwajit P; Eccles SA; Thuwajit C
Clin Breast Cancer; 2017 Oct; 17(6):441-452.e2. PubMed ID: 28533055
[TBL] [Abstract][Full Text] [Related]
4. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.
Lin L; Zhong K; Sun Z; Wu G; Ding G
J Cancer Res Clin Oncol; 2012 Jan; 138(1):11-22. PubMed ID: 21947243
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Sakellariou S; Fragkou P; Levidou G; Gargalionis AN; Piperi C; Dalagiorgou G; Adamopoulos C; Saetta A; Agrogiannis G; Theohari I; Sougioultzis S; Tsioli P; Karavokyros I; Tsavaris N; Kostakis ID; Zizi-Serbetzoglou A; Vandoros GP; Patsouris E; Korkolopoulou P
BMC Cancer; 2016 Mar; 16():174. PubMed ID: 26931562
[TBL] [Abstract][Full Text] [Related]
7. Expression and Significance of High-Mobility Group Protein B1 (HMGB1) and the Receptor for Advanced Glycation End-Product (RAGE) in Knee Osteoarthritis.
Sun XH; Liu Y; Han Y; Wang J
Med Sci Monit; 2016 Jun; 22():2105-12. PubMed ID: 27320800
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of immunogenic cell death biomarker rage and early growth response 1 in human primary gastric adenocarcinoma.
Xu XC; Gao H; Zhang WB; Abuduhadeer X; Wang YH
Int J Immunopathol Pharmacol; 2013; 26(2):485-93. PubMed ID: 23755764
[TBL] [Abstract][Full Text] [Related]
9. Receptors for advanced glycation end products is associated with autophagy in the clear cell renal cell carcinoma.
Guo Y; Zhang HC; Xue S; Zheng JH
J Cancer Res Ther; 2019; 15(2):317-323. PubMed ID: 30964104
[TBL] [Abstract][Full Text] [Related]
10. Research on the relationship between RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer with diabetes mellitus.
Zhou Y; Liu SX; Zhou YN; Wang J; Ji R
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1339-1350. PubMed ID: 33629304
[TBL] [Abstract][Full Text] [Related]
11. Plasma Levels of Receptor for Advanced Glycation End-Products and High-Mobility Group Box 1 in Patients With Pulmonary Hypertension.
Suzuki S; Nakazato K; Sugimoto K; Yoshihisa A; Yamaki T; Kunii H; Suzuki H; Saitoh S; Takeishi Y
Int Heart J; 2016; 57(2):234-40. PubMed ID: 26973260
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma.
Zhu C; Wei J; Tian X; Li Y; Li X
Int J Clin Exp Pathol; 2015; 8(10):12668-77. PubMed ID: 26722456
[TBL] [Abstract][Full Text] [Related]
13. High motility group box 1 (HMGB1) protein and its receptor for advanced glycation end products (RAGE) expression in chronic rhinosinusitis without nasal polyps.
Dzaman K; Zagor M; Molinska-Glura M; Krzeski A
Folia Histochem Cytobiol; 2015; 53(1):70-8. PubMed ID: 25772690
[TBL] [Abstract][Full Text] [Related]
14. Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury.
Gao TL; Yuan XT; Yang D; Dai HL; Wang WJ; Peng X; Shao HJ; Jin ZF; Fu ZJ
J Trauma Acute Care Surg; 2012 Mar; 72(3):643-9. PubMed ID: 22491548
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
Du P; Ye L; Yang Y; Jiang WG
Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of mucin 18 is associated with unfavorable postoperative prognosis in patients with clear cell renal cell carcinoma.
Bai Q; Liu L; Long Q; Xia Y; Wang J; Xu J; Guo J
Int J Clin Exp Pathol; 2015; 8(9):11005-14. PubMed ID: 26617818
[TBL] [Abstract][Full Text] [Related]
17. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas.
Sasahira T; Akama Y; Fujii K; Kuniyasu H
Virchows Arch; 2005 Apr; 446(4):411-5. PubMed ID: 15789216
[TBL] [Abstract][Full Text] [Related]
18. [The expression and clinical significance of Annexin II in clear-cell renal cell carcinoma].
Yang J; Cheng TT; Wang LN; Chen W; Li X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Jan; 28(1):59-62. PubMed ID: 22230505
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
Nguyen AH; Detty SQ; Agrawal DK
Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
[TBL] [Abstract][Full Text] [Related]
20. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
